Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Nilotinib in Metastatic Melanoma With KIT Aberrations

NCT01099514 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01099514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01099514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Nilotinib in Metastatic Melanoma With KIT Aberrations
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2009
Completion date
June 30, 2015
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma with kit aberration